FTC Sues Hims & Hers Over Alleged Data Sharing with Advertisers
· news
FTC Sues Hims & Hers for Allegedly Sharing Private Health Info With Meta and Snap
The telehealth industry has long touted convenience as a key benefit of medical attention from the comfort of one’s own home. However, a recent lawsuit filed by the Federal Trade Commission (FTC) against Hims & Hers, a popular telehealth company, reveals a more insidious reality. The FTC alleges that Hims & Hers engages in deceptive billing practices and shares sensitive health information with third-party advertisers.
According to the FTC’s complaint, customers are often charged before receiving medical attention, contrary to the company’s advertised billing practices. This is not merely a case of sloppy business dealings; it appears to be a deliberate attempt to ensnare patients into recurring subscriptions without their explicit consent. One customer reported being told that no charges would be applied to his card until he spoke with a healthcare professional, only to find out that his account had been charged immediately.
The FTC’s complaint also highlights the company’s alleged sharing of sensitive health information with Meta and Snap. This includes data related to premature ejaculation and erectile dysfunction, areas where consumers might want to keep their health data private from advertisers. The allegations raise serious questions about patient autonomy and trust in telehealth companies.
In response to the lawsuit, Hims & Hers has claimed that the FTC is “ignoring established state laws and industry standards” in telehealth. This tactic is a common corporate defense strategy, one that shifts responsibility away from company actions. However, it rings hollow when considering the complexity of telemedicine and the ease with which sensitive data can be mishandled.
The redacted portions of the FTC’s complaint only add to the mystery, raising more questions than answers about what information is being withheld from public view. The lack of transparency here is just as troubling as the allegations themselves.
The case serves as a stark reminder that patients’ rights and data protection remain woefully underprioritized in the telehealth industry. It’s time for regulators to take a closer look at how telehealth companies operate and hold them accountable for their actions. The FTC’s complaint is a step in the right direction, but it’s only the beginning.
As healthcare technology becomes increasingly sophisticated, patients must be remembered as more than just data points or product testers – they have rights that demand respect and protection from those who seek to profit from their most intimate secrets.
Reader Views
- CMColumnist M. Reid · opinion columnist
The FTC's lawsuit against Hims & Hers highlights a critical blind spot in telehealth regulation: the lack of transparency around data sharing. While the company's alleged practice of charging patients before treatment is concerning, the real issue lies in how they're using that data to target vulnerable individuals with predatory advertising. The intersection of consumer health and corporate profit needs closer scrutiny – not just because of the financial exploitation, but also because of the potential harm caused by normalizing shame around sensitive medical issues.
- RJReporter J. Avery · staff reporter
This lawsuit shines a much-needed light on the lax data protection measures of telehealth companies like Hims & Hers. While the FTC's allegations are concerning enough, we should also be examining the broader implications for patient confidentiality in this rapidly growing industry. Specifically, what safeguards exist to prevent unauthorized sharing of sensitive health information with third-party platforms? And how will patients who have already entrusted their data to these companies be protected from potential exploitation?
- EKEditor K. Wells · editor
The FTC's lawsuit against Hims & Hers highlights a critical flaw in the telehealth model: a lack of transparency and accountability when it comes to billing practices and data sharing. What's striking is how often these companies rely on fine print and clever language to deceive patients into recurring subscriptions, leaving them wondering where their money goes. It's time for stricter regulations and clear guidelines for patient consent – anything less risks eroding trust in a service that's meant to be convenient, not exploitative.